MY126132A - Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases - Google Patents

Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases

Info

Publication number
MY126132A
MY126132A MYPI20013985A MYPI20013985A MY126132A MY 126132 A MY126132 A MY 126132A MY PI20013985 A MYPI20013985 A MY PI20013985A MY PI20013985 A MYPI20013985 A MY PI20013985A MY 126132 A MY126132 A MY 126132A
Authority
MY
Malaysia
Prior art keywords
signal transduction
tyrosine kinases
aminoquinazolines
inhibit signal
transduction mediated
Prior art date
Application number
MYPI20013985A
Inventor
Frank Dr Himmelsbach
Elke Dr Langkopf
Birgit Dr Jung
Stefan Dr Blech
Flavia Dr Solca
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MY126132A publication Critical patent/MY126132A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOUNDS OF THE FORMULA HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION BY TYROSINE KINASES AND THEIR USE IN THE TREATMENT DISEASES, ESPECIALLY TUMORAL DISEASES AND DISEASES LUNGS AND AIRWAYS, AND THE PREPARATION THEREOF. MEDIATED OF THE
MYPI20013985A 2000-08-26 2001-08-24 Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases MY126132A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10042058A DE10042058A1 (en) 2000-08-26 2000-08-26 Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation

Publications (1)

Publication Number Publication Date
MY126132A true MY126132A (en) 2006-09-29

Family

ID=7653945

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20013985A MY126132A (en) 2000-08-26 2001-08-24 Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases

Country Status (31)

Country Link
EP (1) EP1315705A1 (en)
JP (1) JP4834282B2 (en)
KR (1) KR100862873B1 (en)
CN (1) CN100404517C (en)
AR (1) AR033562A1 (en)
AU (2) AU2001287694B2 (en)
BG (1) BG107559A (en)
BR (1) BR0113519A (en)
CA (1) CA2417897C (en)
CZ (1) CZ302567B6 (en)
DE (1) DE10042058A1 (en)
EA (1) EA005679B1 (en)
EC (1) ECSP034464A (en)
EE (1) EE05269B1 (en)
HK (1) HK1057557A1 (en)
HR (1) HRP20030138A2 (en)
HU (1) HUP0300819A3 (en)
IL (2) IL154602A0 (en)
ME (1) MEP58708A (en)
MX (1) MXPA03001483A (en)
MY (1) MY126132A (en)
NO (1) NO324866B1 (en)
NZ (1) NZ524668A (en)
PL (1) PL360248A1 (en)
RS (1) RS52279B (en)
SK (1) SK287747B6 (en)
TW (1) TWI294422B (en)
UA (1) UA73004C2 (en)
UY (1) UY26903A1 (en)
WO (1) WO2002018351A1 (en)
ZA (1) ZA200300991B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004981B1 (en) 1999-06-21 2004-10-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
DE10042059A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
RS85404A (en) * 2002-03-30 2007-02-05 Boehringer Ingelheim Pharma Gmbh. & Co.Kg., 4-(n-phenylamino)- quinazolines/quinolines as tyrosine kinase inhibitors
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10214412A1 (en) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and process for their preparation
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
DE10326186A1 (en) * 2003-06-06 2004-12-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10334226A1 (en) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
AU2004274227B2 (en) 2003-09-19 2008-04-24 Astrazeneca Ab Quinazoline derivatives
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
DE10345875A1 (en) * 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods of preparation
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10350717A1 (en) * 2003-10-30 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
AR055564A1 (en) 2005-02-26 2007-08-22 Astrazeneca Ab QUINAZOLINE DERIVATIVES
KR100673775B1 (en) * 2005-04-08 2007-01-24 엘지전자 주식회사 Home bar door of refrigerator
EP1919900A2 (en) * 2005-08-22 2008-05-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
CA2643363A1 (en) * 2006-03-09 2007-09-13 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them
RU2492864C2 (en) 2006-09-18 2013-09-20 Бёрингер Ингельхайм Интернациональ Гмбх Method of treating cancer carrying egfr mutations
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
EA200901041A1 (en) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх BICYCLIC HETEROCYCLES CONTAINING THESE COMPOUNDS MEDICINES, THEIR APPLICATION AND METHOD OF OBTAINING THEM
EA019709B1 (en) 2008-02-07 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Spirocyclic heterocycles and use thereof as medicaments
EP2303276B1 (en) 2008-05-13 2013-11-13 AstraZeneca AB Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
HUE044629T2 (en) 2009-07-06 2019-11-28 Boehringer Ingelheim Int Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
KR101317809B1 (en) 2011-06-07 2013-10-16 한미약품 주식회사 Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant
KR20140096571A (en) 2013-01-28 2014-08-06 한미약품 주식회사 Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one
ES2642201T3 (en) 2013-03-06 2017-11-15 Astrazeneca Ab Quinazoline inhibitors of mutant forms of epidermal growth factor receptor activation
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CR20160463A (en) * 2014-04-04 2017-03-06 H Lundbeck As QUINAZOLIN-THF-AMINAS HALOGENATED AS PDE1 INHIBITORS
US20170176028A1 (en) 2015-12-18 2017-06-22 Lg Electronics Inc. Air conditioner
US11446302B2 (en) 2016-11-17 2022-09-20 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
CN112321814B (en) * 2020-12-30 2021-03-23 广州初曲科技有限公司 Preparation and application of gefitinib idebenone conjugate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) * 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
KR100489174B1 (en) * 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-anilinoquinazoline derivatives
CN100503580C (en) * 1996-04-12 2009-06-24 沃尼尔·朗伯公司 Irreversible inhibitor of tyrosine kinase
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19911509A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation

Also Published As

Publication number Publication date
KR20030024914A (en) 2003-03-26
HRP20030138A2 (en) 2005-04-30
AU8769401A (en) 2002-03-13
IL154602A (en) 2008-07-08
HUP0300819A2 (en) 2003-09-29
ZA200300991B (en) 2004-04-16
DE10042058A1 (en) 2002-03-07
RS52279B (en) 2012-10-31
WO2002018351A1 (en) 2002-03-07
PL360248A1 (en) 2004-09-06
HK1057557A1 (en) 2004-04-08
YU14003A (en) 2006-01-16
EA200300219A1 (en) 2003-08-28
SK287747B6 (en) 2011-08-04
NO20030870L (en) 2003-02-25
CZ302567B6 (en) 2011-07-13
EE05269B1 (en) 2010-02-15
MEP58708A (en) 2011-05-10
KR100862873B1 (en) 2008-10-15
JP4834282B2 (en) 2011-12-14
BR0113519A (en) 2003-07-01
JP2004507529A (en) 2004-03-11
TWI294422B (en) 2008-03-11
NO20030870D0 (en) 2003-02-25
EE200300077A (en) 2004-12-15
NO324866B1 (en) 2007-12-17
MXPA03001483A (en) 2003-06-06
CN1449390A (en) 2003-10-15
BG107559A (en) 2003-10-31
CA2417897A1 (en) 2003-01-30
NZ524668A (en) 2006-06-30
CA2417897C (en) 2009-03-31
IL154602A0 (en) 2003-09-17
UY26903A1 (en) 2002-03-22
UA73004C2 (en) 2005-05-16
HUP0300819A3 (en) 2008-03-28
EA005679B1 (en) 2005-04-28
AR033562A1 (en) 2003-12-26
EP1315705A1 (en) 2003-06-04
AU2001287694B2 (en) 2007-09-06
CN100404517C (en) 2008-07-23
ECSP034464A (en) 2003-03-31
SK2312003A3 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
MY126132A (en) Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
MY136086A (en) Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
MXPA04003668A (en) Type 4 phosphodiesterase inhibitors and uses thereof.
MY127771A (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CY1107054T1 (en) KINAZOLIN SOLUTION BITS
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
WO2002069945A3 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
IL173916A0 (en) Thienopyrazoles
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
PL351125A1 (en) Derivatives of 4,5-diaryl-3(2)-furanone as inhibitors of cykoxygenease-2
TW200730508A (en) Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same
CO5660287A2 (en) DERIVATIVES OF TETRAHYDROCARBAZOL AND ITS PHARMACEUTICAL USE
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
AP2004002995A0 (en) Combination therapy for the treatment of cancer
TW200505912A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE60312736D1 (en) 1,2,4-TRIAMINOBENZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
TW200510341A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
MXPA04005809A (en) Protein kinase inhibitors.
MXPA04003910A (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension.
PT1255538E (en) USE OF 2-METHYL-THIAZOLIDIN-2,4-DICARBOXYLIC ACID AND / OR PHYSIOLOGICAL COMPATIBLE SATISTS FOR TREATMENT AND / OR PREVENTION OF CANCERS
TW200504051A (en) Novel acridine derivatives and their use as medicaments
MXPA02012165A (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites.
EA200500865A1 (en) SYNERGETIC COMBINATION INCLUDING ROFLUMILAST AND R, R-FORMOTEROL